| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S100Z |
| Uniprot No | Q8WXG8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-99aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MPTQLEMAMD TMIRIFHRYS GKERKRFKLS KGELKLLLQR ELTEFLSCQK ETQLVDKIVQ |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S100Z重组蛋白的模拟参考文献(请注意，以下内容为示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*Recombinant S100Z Protein Expression and Its Role in Inflammatory Signaling*
**作者**：Smith A, et al.
**摘要**：研究报道了在大肠杆菌中高效表达重组人S100Z蛋白的方法，并发现其通过激活NF-κB通路促进巨噬细胞的炎症反应，提示其在慢性炎症疾病中的潜在作用。
2. **文献名称**：*Structural Characterization of S100Z and Its Calcium-Dependent Interactions*
**作者**：Zhang L, et al.
**摘要**：通过X射线晶体学解析了重组S100Z的钙结合结构域，揭示了其与靶蛋白(如RAGE受体)结合的分子机制，为开发靶向抑制剂提供了结构基础。
3. **文献名称**：*S100Z Overexpression in Colorectal Cancer: Implications for Prognosis and Therapy*
**作者**：Wang Y, et al.
**摘要**：利用重组S100Z蛋白进行功能实验，发现其在结直肠癌细胞中通过调控Wnt/β-catenin通路促进侵袭转移，提示其可作为肿瘤治疗的潜在靶点。
4. **文献名称**：*Comparative Analysis of S100Z and S100A8/A9 in Immune Regulation*
**作者**：Müller K, et al.
**摘要**：对比重组S100Z与S100A8/A9的免疫调节功能，发现S100Z在单核细胞趋化中具有独特作用，可能通过TLR4信号通路调控先天免疫应答。
---
**注意**：以上文献信息为模拟生成，实际研究中请通过PubMed、Web of Science或Google Scholar等平台以“S100Z recombinant protein”为关键词检索最新论文。S100Z的研究尚处于早期阶段，建议结合S100蛋白家族其他成员(如S100A8/A9)的相关文献扩展分析。
The S100Z protein is a member of the S100 family of calcium-binding proteins, which play diverse roles in cellular processes such as inflammation, differentiation, and cancer progression. S100Z, also termed S100 calcium-binding protein Z, shares structural features with other S100 proteins, including EF-hand domains that enable calcium-dependent interactions with target proteins. While its exact biological functions remain less characterized compared to well-studied family members like S100A8/A9 or S100B, emerging evidence suggests S100Z may regulate immune responses, cell proliferation, and intracellular signaling pathways. Dysregulation of S100Z expression has been loosely associated with certain cancers, though its mechanistic contributions require further investigation.
Recombinant S100Z protein is produced using genetic engineering techniques, typically through heterologous expression in bacterial (e.g., *E. coli*) or mammalian cell systems. This approach ensures high purity and consistent quality for research applications. The recombinant form retains calcium-binding capacity and structural stability, enabling in vitro studies to dissect its interactions with binding partners, such as receptors or enzymes. Tagging systems (e.g., His-tag) are often incorporated to facilitate purification and detection.
Interest in recombinant S100Z stems from its potential as a biomarker or therapeutic target. Researchers utilize it to explore its role in disease models, particularly in contexts where S100 proteins mediate inflammatory or oncogenic pathways. Additionally, it serves as an antigen for antibody development in diagnostic assays. Despite its understudied status, S100Z represents a valuable tool for unraveling the complexity of S100 protein networks and their implications in human health and disease. Ongoing studies aim to clarify its physiological relevance and translational potential.
×
